Antibacterial Agents TRIZ Cases

Cyclodextrin inclusion complexes shield bacteriophages from thermal and mechanical stress during spray drying, enabling stable solid oral dosage forms.

Neutral methylphosphonate linkages in morpholino oligomers eliminate electrostatic repulsion while maintaining nuclease resistance.

Moulded platelet gel restores breast volume while reducing surgical morbidity and avoiding synthetic implant complications.

Intermediate filament peptides target specific tissues to inhibit cell proliferation, reducing side effects from non-specific antimitotic action.

Positively charged beta-lactam prodrugs penetrate skin and blood-brain barriers via electrostatic attraction, bypassing painful injections.

Preliminary sow vaccination transfers antibodies to piglets, resolving the conflict between early protection and neutralizing maternal antibodies.

Formula I heterocyclic compounds target the HCV NS5B polymerase to resolve inadequate treatment effectiveness and insufficient viral replication inhibition.

A bispecific antibody uses knob-into-hole conformational pairing to stabilize heterodimer formation.

Template-induced folding stabilizes beta-hairpin conformation to resolve affinity and selectivity trade-offs in FPR1 modulation.

Modified molecular frameworks enable selective receptor binding, suppressing supraphysiologic peak levels while maintaining therapeutic efficacy.

Formula I compounds inhibit Btk to reduce inflammatory responses while maintaining manufacturing simplicity.

Segmenting non-ribosomal peptide synthetases into exchange units resolves domain compatibility issues to synthesize diverse peptides.

A soluble antigenic extract from Rhodococcus equi membranes uses nonionic detergents to solubilize bacterial components for vaccine preparation.

Heterologous VSV serotypes in a prime-boost regimen avoid neutralization to enhance immune response efficacy.

Attenuated alpha-hemolysin toxin stimulates protective antibodies, reducing bacterial load and mortality in staphylococcal pneumonia.

Seven-membered ring peptidomimetics resist proteolysis degradation while binding PRM domains.

Marine sediment-derived actinomycetes produce the novel xanthon compound MBL-AB01 using seawater-based culture media and dimethyl sulfoxide extraction.

Novel pyrrolo[3,2-d]pyrimidine compounds act as selective Toll-like receptor 7 agonists to induce human interferon-alpha production.

Altered fHbp affinity reduces epitope masking to trigger protective immunity.

Synthesized 7-alkynyl-1,8-naphthyridone derivatives inhibit the VEGFR-3 enzyme.

Acetyl-CoA carboxylase inhibitors block fatty acid synthesis to reduce body fat.

pH-sensitive antibody design reduces in vivo physiological activity by promoting rapid antigen clearance from plasma while extending circulation half-life.

Basic amino acid counterions shield pentadecapeptides from pepsin degradation in gastric juice.

Glycoside hydrolases break down the protective extracellular polymeric substance matrix, allowing antibiotics to penetrate and treat resistant infections.

Inter-alpha inhibitor proteins address inadequate inflammatory control by reducing inflammation and promoting tissue repair in the lung.

TAM receptor agonists and inhibitors modulate immune activity to treat autoimmune disorders and sepsis without broad immunosuppression side effects.

A lock mechanism limits pump actuations to prevent over-administration and reduce medication waste.

A pleuromulin rhein ester hybrid molecule combines ribosome targeting with membrane disruption to inhibit bacterial growth.

Optimized CpG oligodeoxynucleotides resolve species specificity issues in poultry vaccines by leveraging TLR21 recognition motifs.

Combines fulvic acid with antibiotics to inhibit resistant bacterial growth and prevent resistance development.

Engineered antibodies target amyloid beta protofibrils with high affinity to enable selective clearance across the blood-brain barrier.

Pre-implantation factor peptide modulates potassium channels to neutralize local immune suppression and increase cytokine secretion for treating tuberculosis.

Bioactive self-assembling peptide forms nanofibers to activate human mast cells locally, reducing systemic side effects from traditional activation methods.

UspA2 protein constructs form immunogenic compositions that elicit protective immune responses against bacterial pathogens.

Complexing gentamicin with smectite clay mineral targets Helicobacter pylori on gastric mucosa, avoiding systemic absorption.

Targeted monoclonal antibodies neutralize Clostridium difficile toxins A and B, preventing relapse without disrupting normal gut flora.

Serine and zinc salts reduce oral biofilm formation, addressing inadequate bacterial control from conventional zinc compounds.

Novel carbapenem derivatives target bacterial Penicillin Binding Proteins to provide broad-spectrum antibacterial activity.

A low molecular weight immunostimulant derived from degraded symbiotic bacteria activates innate immune receptors to enhance disease treatment.

Engineered Salmonella vaccine strain expresses phage holin and lysozyme to reduce colonization in chickens.

Agarobiose suppresses Streptococcus mutans growth at lower concentrations than xylitol, resolving the trade-off between efficacy and dosage requirements.

PIM-1 encoding nucleic acids restore insufficient kinase levels in heart tissue, reversing circulatory system injuries through targeted gene expression.

Modified immunoregulatory polynucleotides block TLR9 activation to prevent unwanted immune activation in autoimmune therapies.